



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# Translating benefit-risk information into product information

---

PCWP and HCPWP joint meeting  
Workshop on regulatory and methodological standards to  
improve benefit/risk evaluation of medicines

Laurent Brassart  
Stakeholders and Communication Division

An agency of the European Union





# EU product information

Package Leaflet

Assessment report

Summary of Product Characteristics



Home Find medicine Regulatory Special topics Document search News & events Partners & networks About us Quick links

Follow us: [Twitter] [Facebook]

Home Find medicine Human medicines

Human medicines

- European public assessment reports
- Patient safety
- Pending EC decisions
- Withdrawn applications

## European Public Assessment Report

Email Print Help Share

About Authorisation details Product information Assessment history

Next tab »

**AUTHORISED**  
This medicine is approved for use in






## EMA/PCWP/HCP WG report on information on benefit-risk of medicines *(23 June 2009, EMA/40926/2009)*

- ❖ Assessment at population level vs individual use
  - Always communicate benefits and risks together
  - Clear information to help choose most appropriate treatment
  - Clear description of benefits and risks, both qualitative and quantitative
  - Factors which may influence a benefit or a risk in an individual should be clearly described
  
- ❑ Concise information + detailed data



# Summary of product characteristics (SmPC) - What is it and what does it contain?





## SmPC information on benefits

Section 5.1 “**Pharmacodynamic properties**” summarises the benefits of the medicine in presenting:

- Its mechanism of action
- The main results of the clinical trials supporting the marketing authorisation
  - In giving the main characteristics of the patient population studied
  - And presenting the effects qualitatively and quantitatively
- Additional clinically relevant information in special populations:
  - In a balanced way (i.e. informing on uncertainties as appropriate)
  - Including study results in the paediatric population




## SmPC information on risks

- Section 4.8 “**Undesirable effects**” provides:
  - A **summary of safety profile** (most serious and most frequently occurring adverse reactions)
  - A tabulated list of all adverse reactions with their respective frequency category
  - Information characterising specific adverse reaction
  - Information on clinically relevant differences in special population
- Information on a specific risk is also reflected in section 4.4 “Special warnings and precautions for use” when the risk leads to a precaution for use or when healthcare professionals have to be warned of this risk



## SmPC information for individualised care

- SmPC information first addresses the recommendations that apply to the general population
- The SmPC also provides dedicated information for these groups of patients, when relevant information is available
- Information can be presented under specific subheading within each relevant section of the SmPC
  - Paediatric population, Elderly, Hepatic or renal impairment, Other concomitant diseases, Genomic factors, ...
- Or in dedicated section;
  - e.g. Drug interaction, Pregnancy/Lactation, Driving, Overdose

**Regulatory**  
**Rapporteur**

JULY/AUGUST 2013

THE INTERNATIONAL JOURNAL FOR PROFESSIONALS IN REGULATORY AFFAIRS

## BRINGING THE OLD INTO THE FOLD

Initiatives to make medical treatments safer and more user-friendly for older patients

**PLUS**  
Measuring benefit-risk | Challenges in paediatric medicines | Progress on global harmonisation | A modern approach to document management

TOPRA  
PUBLISHING

## Product information and older people: how to assist informed prescription and safe therapeutic use

### Authors

**Laurent Brassart**, Information Compliance and Consistency, European Medicines Agency; **Alexios Skarlatos**, Section Head for Product Information Quality, European Medicines Agency; **Lucia Camanas Saez**, European Medicines Agency; **Francesca Cerreta**, Geriatric Medicines topic leader, European Medicines Agency.

### Keywords

Older people; Product information; Summary of product characteristics (SmPC); Package leaflet; Co-morbidity; European Medicines Agency (EMA); Polypharmacy; Clinical trials; Adverse reaction reporting; Treatment adherence; Formulation; Packaging.

### Abstract

Older people are the fastest growing population group and often the main users of medicines. Despite some challenges, it is possible to improve information on the use of medicines in older people, which will help in increasing safe and effective use, including treatment adherence. Provision of good information relies on collection of adequate data both before and after marketing authorisation. The summary of product characteristics (SmPC) should reflect the current knowledge and experience in older people, in particular any clinically relevant identified differences with the younger population. Because of the higher co-morbidity, clear information on risk factors and drug interactions will be of utmost value for older people. Consistent information should be presented in the package leaflet, which plays an important role in assisting patients to adhere and use the medicine safely. Attention should also be paid to older people's needs in terms of formulation, packaging design and readability of the package leaflet. The European Medicines Agency's related initiatives are presented in this article.

### Introduction

Worldwide, we are experiencing a demographic shift towards an older population, with the very old (>80 years) representing the fastest growing population group. In Europe, the old-age dependency ratio (the ratio of those over retirement age to those of working age) is projected to more than double, from 26.2% in 2011 to 52.6% by 2060.<sup>1</sup>

In many therapeutic areas, older people are the major users of medications, and polypharmacy plays an important role, with a mean of five medications per person.<sup>2</sup> How is the regulatory system adapting to the challenges posed by an ageing population?

In 2011, the European Medicines Agency (EMA) adopted its geriatric medicines strategy,<sup>3</sup> based on two main pillars:

- The demonstration of an appropriate benefit-risk balance in the population that will use the medication
- The appropriate reflection of these findings in the "product information" in order to assist informed prescription and safe use.

Drug development requirements in the elderly are addressed by the recent Question and Answers addition to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E7 guideline.<sup>4</sup>

In this article we explore challenges and possible solutions to the problem of providing concise, accurate, safety and efficacy data relevant to prescribing medicines for older people, and how the packaging and product information (SmPC, package leaflet and labels) could help in increasing treatment adherence.

### Focusing on the needs of a real-life population

When developing and evaluating a medicine, we should keep in focus the people who will ultimately use it, and what their needs are. Chronic illness, complex medication regimens, and polypharmacy are significant risk factors for drug interactions and poor treatment adherence; in addition, changes in drug pharmacokinetics and pharmacodynamics put the older population at increased risk of adverse reactions. When significant use of a drug is expected in older patients, particular consideration of their specific needs should be integrated into the development and evaluation of medicines, which must take into account how medicines will be used in practice.

The ability to take or administer medicinal products as intended may be affected by a number of physical factors, such as poor hydration, poor dexterity, visual and cognitive impairment, swallowing difficulties and gastrointestinal changes. Reading labels or package leaflets, opening packaging, swallowing tablets – all seemingly simple tasks – can turn into barriers to correct use as one ages.

Medication non-adherence, which is due to numerous preventable factors, affects all age groups, but older adults face increased risk due to polypharmacy. Non-adherence impacts directly on the patient's clinical management and can lead to considerable disability, morbidity, increased numbers of emergency visits, prolonged hospital stays, re-admissions and even increased mortality.

A wide range of erroneous medication-taking behaviours have been identified: omitting or multiplying doses; discontinuing medication prematurely; taking medication at the wrong time; or storing it inappropriately.

Appropriate product information, packaging and pharmaceutical drug design can and should assist in overcoming these problems.

The EMA has a strong working relationship with patients and healthcare professionals:<sup>5</sup> the agency's message is that it considers as a priority the provision of high quality information on medicines, tailored to the specific needs of the individual patient, and the need for relevant information on geriatric medicines was acknowledged at the March 2012 EMA workshop on medicines for older people.

### Need for evidence-based information

In order to be able to provide accurate information to the patient and the prescriber, the first requirement is the establishment of the benefit-risk balance. This concept is meaningful only within the



# SmPC challenges in practice

- Concise vs comprehensive information / Transparent vs unduly alarming
  - Efficacy - Main results (statistically compelling and clinically relevant)
  - Safety - Causal relationship – Frequency of adverse reactions
  - Subpopulation with relevant clinical different efficacy or safety
  - Missing information
  - Drug interactions
- Consistency between products and with therapeutic guidelines




# Which efficacy results?

## Examples of endpoints in Rheumatoid Arthritis


- ACR20 (50, 70) response criteria
- DAS28
- swollen joint count
- tender joint count
- Patient pain
- physical function (e.g. HAQ, AIMS)
- patient global assessment of disease
- physician global assessment of disease
- Clinical remission
- radiographic evidence
- acute phase reactants (e.g. erythrocyte sedimentation rate, C-reactive protein)
- ...

## Example of analyses





# Which safety information?





# Consistency between products and with therapeutic guidelines

- Products developed at different times
- Different developments (endpoints, standard of care, populations, vs placebo or active comparator, in monotherapy or in combination, ...)
- Different companies and marketing authorisation procedures
- Different standards of care
- Science is evolving



# Promoting compliance and consistency

## SmPC Advisory Group

The screenshot shows the EMA website page for 'How to prepare and review a summary of product characteristics (SmPCs) for human medicines'. The page includes a navigation menu, a search bar, and a main content area with a video player and a table of contents.

**Navigation:** Home, Find medicine, Regulatory, Special topics, Document search, News & events, Partners & networks, About us

**Text size:** [A] [A] [A] **Site-wide search:** [GO]

**Follow us:** [Twitter] [Facebook] [LinkedIn] [YouTube] [RSS]

**Quick links:** [Icon]

**Human medicines**

- Pre-authorisation
- Post-opinion
- Post-authorisation
- Product information
  - Modi-ups and specimens
  - Linguistic review
  - Product information templates
  - How to prepare an SmPC
  - QRD reference documents and guidelines
  - Croatian pre-accession linguistic check
  - Guidance
    - Scientific advice and protocol assistance
    - Scientific guidelines
    - Innovation Task Force
    - Regulatory and procedural guidance
    - SME office
    - Paediatric medicine
    - Orphan designation
    - Herbal products
    - Referral procedures
    - Article 58 applications
    - Compassionate use
    - Pharmacovigilance
    - Advanced therapies
    - Inspections
    - Quality by design
    - Product defects and recalls
    - Parallel distribution
    - Medicine shortages
    - Pandemic influenza
    - Non-pharmaceutical products
    - New countries/EFTA
    - Fees
    - Veterinary medicines

**How to prepare and review a summary of product characteristics (SmPCs) for human medicines**

**This page includes guidance for pharmaceutical companies on how to prepare and review summaries of product characteristics (SmPCs) for human medicines.**

The guidance, prepared by the Agency's SmPC Advisory Group, outlines the principles in the European Commission's guideline on SmPC<sup>07</sup>.

It is intended to enable companies to make sure that the information in SmPCs is of high quality when they submit them to the Agency as part of applications for new marketing authorisations or updates to existing marketing authorisations. It also aims to raise awareness of the information provided in SmPCs among healthcare professionals.

**SmPCs**

SmPCs are a key part of the marketing authorisation of all medicines authorised in the European Union and the basis of information for healthcare professionals on how to use a medicine safely and effectively. They are kept updated throughout the lifecycle of a medicine as new efficacy or safety data emerge.

SmPCs are also the basis for the preparation of package leaflets, so are important documents in enabling information on medicines to reach patients.

**Introduction to the SmPC**

**SmPC guideline**

**Summary of product characteristics (SmPC) - What is it and what does it contain?**

**Table of contents**

- Training presentations
- Scientific guidelines with SmPC recommendations

**Training presentations**

| Document(s)   | Language       | Status | First published | Last updated | Effective Date |
|---|----------------|--------|-----------------|--------------|----------------|
| Presentation - SmPC training presentations user guide                           | (English only) |        | 21/01/2013      |              |                |
| Presentation - Introduction to the summary-of-product-characteristics guideline | (English only) |        | 21/01/2013      |              |                |
| Presentation - Section 1: Name of medicinal product                             | (English only) |        | 21/01/2013      |              |                |
| Presentation - Section 2: Qualitative and quantitative composition              | (English only) |        | 21/01/2013      |              |                |
| Presentation - Section 3:   |                |        |                 |              |                |



## Package leaflet

- Information on benefit-risk of medicines: patients', consumers' and healthcare professionals' expectations - EMEA/40926/2009
  - *“the package leaflet could progress from a document on the use of the medicine (which may create fear in patients when reading the warnings and list of undesirable effects) toward an “information tool”. It should provide more information on benefits in understandable terms.”*
- To help supporting adherence to treatment



# QRD product information annotated template (from July 2011) - benefits

## [Information on the benefits of using this medicine]

[On a case-by-case basis, information on the benefits of the treatment could be included in this section, as long as it is compatible with the SmPC, useful for the patient, and to the exclusion of any element of a promotional nature (in accordance with art 62 of Directive 2001/83/EC). This could be included under a separate subheading, e.g. entitled “How X works”.

The information should be depicted in a clear and condensed way. For example, information could relate to:

- signs and symptoms of the target disease, in particular for non-prescription medicines, but also for medicines to be taken “on-demand” (e.g. treatment of migraine);
- the benefit(s) of taking the medicine could be summarised (e.g. “this medicine reduces pain associated with arthritis”, “this medicine has been shown to reduce blood sugar, which helps to prevent complications from your diabetes”). This would be particularly important to encourage adherence to the treatment, e.g. for long-term and prevention treatment. Benefit may be described in terms of prevention of disease complications (e.g. anti-diabetic), if established. The timing of the effect may also be described if useful. In any case, information must be compatible with the SmPC, in particular section 5.1;
- information on the amount of time the medicine usually takes to work may be presented if relevant for the patient (pain-killer, antidepressant, etc).

<You must talk to a doctor if you do not feel better or if you feel worse <after {number of} days>.>.]



## Information on benefit in the PL

- Clinical trials data should be interpreted in their context
- How far can results be presented qualitatively and quantitatively in the PL in lay language?
- Are quantitative measures suitable in the PL or should information be presented semi-quantitatively (e.g. delay, reduce, improve, prevent)?
- Could comparative benefit information be presented?
  - vs placebo?
  - vs active comparator?

Is information robust, evidence-based, clinically relevant and patient-oriented?



# QRD product information annotated template

## 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

[The section should generally be divided into two sections bearing in mind that there should be sufficient patient-friendly description of the overt clinical signs and symptoms to enable the patient to recognise all side effects which may occur as set out in section 4.8 of the SmPC:

- 1) the most serious side effects need to be listed prominently first with clear instructions to the patients on what action to take (e.g. to stop taking the medicine and/or seek urgent medical advice. The use of the words “straight away” or “immediately” may be helpful in this context).
- 2) then a list of all other side effects, listed by frequency and starting with the most frequent (without repeating the most serious included above).

Within each section mentioned above, side effects should be arranged by frequency. The following frequency convention is recommended:

### *Reporting of side effects*




## Area for future discussion?

- More information?
  - Comparative data?
  - Reference to therapeutic guideline?
- Abstract?
- Link to other documents (assessment reports, RMP, PL, ...)?
- Increased granularity?
- More involvement of stakeholders in SmPC review (two-way communication + value judgement)?
- ... *eHealth (e-prescribing tools) context?*



# Strengthening the link between the different information?





# Strengthening the link between the different information?

